Onward Therapeutics
Stories
-
Onward Therapeutics closes NT$900 million Series B financing
Onward Therapeutics, Inc. announced it has closed a NT$900 million (approximately US$28 million) Series B financing, its first capital increase in Taiwan since it completed its share exchange and moved its global headquarters from Switzerland to Taiwan in October 2025. Proceeds will fund the Company's clinical programs, the manufacturing of clinical supplies, and early-stage R&D.